Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature
It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of devel...
Gespeichert in:
| Veröffentlicht in: | Seminars in thrombosis and hemostasis Jg. 38; H. 5; S. 535 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.07.2012
|
| Schlagworte: | |
| ISSN: | 1098-9064, 1098-9064 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of developing venous thromboembolism (VTE), we conducted a meta-analysis of the existing literature. After an electronic search strategy using Medline and Embase and a manual review of abstract books of the International Society on Thrombosis and Haemostasis and of reference lists of all retrieved articles, we included in the systematic review 38 studies with 10,305 VTE cases. The prevalence of non-O blood group was significantly higher in VTE patients compared with controls with a resulting pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38; p < 0.00001). Similar findings were obtained when the genotypes A1O/BO/A2B (OR 1.73, 95% CI, 1.47, 2.05; p < 0.00001) and A1B/A1A1/BB (OR 1.87, 95% CI, 1.84, 2.44; p < 0.00001) were analyzed. The maximum VTE risk was observed in non-O-factor V Leiden patients (OR 7.60, 95% CI, 3.21, 17.99), while for G20210A prothrombin mutation it was not possible to perform a pooled analysis due to a paucity of published studies. Finally, the association between non-O blood group and VTE was weaker when provoked VTE cases were considered (OR 1.33, 95% CI, 1.18, 1.50), while it was substantially unchanged when unprovoked VTE cases were analyzed (OR 1.88, 95% CI, 1.42, 2.50). In conclusion, considering its prevalence, non-O blood group is a candidate to be one of the most important genetic risk factors for venous thrombosis. |
|---|---|
| AbstractList | It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of developing venous thromboembolism (VTE), we conducted a meta-analysis of the existing literature. After an electronic search strategy using Medline and Embase and a manual review of abstract books of the International Society on Thrombosis and Haemostasis and of reference lists of all retrieved articles, we included in the systematic review 38 studies with 10,305 VTE cases. The prevalence of non-O blood group was significantly higher in VTE patients compared with controls with a resulting pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38; p < 0.00001). Similar findings were obtained when the genotypes A1O/BO/A2B (OR 1.73, 95% CI, 1.47, 2.05; p < 0.00001) and A1B/A1A1/BB (OR 1.87, 95% CI, 1.84, 2.44; p < 0.00001) were analyzed. The maximum VTE risk was observed in non-O-factor V Leiden patients (OR 7.60, 95% CI, 3.21, 17.99), while for G20210A prothrombin mutation it was not possible to perform a pooled analysis due to a paucity of published studies. Finally, the association between non-O blood group and VTE was weaker when provoked VTE cases were considered (OR 1.33, 95% CI, 1.18, 1.50), while it was substantially unchanged when unprovoked VTE cases were analyzed (OR 1.88, 95% CI, 1.42, 2.50). In conclusion, considering its prevalence, non-O blood group is a candidate to be one of the most important genetic risk factors for venous thrombosis.It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of developing venous thromboembolism (VTE), we conducted a meta-analysis of the existing literature. After an electronic search strategy using Medline and Embase and a manual review of abstract books of the International Society on Thrombosis and Haemostasis and of reference lists of all retrieved articles, we included in the systematic review 38 studies with 10,305 VTE cases. The prevalence of non-O blood group was significantly higher in VTE patients compared with controls with a resulting pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38; p < 0.00001). Similar findings were obtained when the genotypes A1O/BO/A2B (OR 1.73, 95% CI, 1.47, 2.05; p < 0.00001) and A1B/A1A1/BB (OR 1.87, 95% CI, 1.84, 2.44; p < 0.00001) were analyzed. The maximum VTE risk was observed in non-O-factor V Leiden patients (OR 7.60, 95% CI, 3.21, 17.99), while for G20210A prothrombin mutation it was not possible to perform a pooled analysis due to a paucity of published studies. Finally, the association between non-O blood group and VTE was weaker when provoked VTE cases were considered (OR 1.33, 95% CI, 1.18, 1.50), while it was substantially unchanged when unprovoked VTE cases were analyzed (OR 1.88, 95% CI, 1.42, 2.50). In conclusion, considering its prevalence, non-O blood group is a candidate to be one of the most important genetic risk factors for venous thrombosis. It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of developing venous thromboembolism (VTE), we conducted a meta-analysis of the existing literature. After an electronic search strategy using Medline and Embase and a manual review of abstract books of the International Society on Thrombosis and Haemostasis and of reference lists of all retrieved articles, we included in the systematic review 38 studies with 10,305 VTE cases. The prevalence of non-O blood group was significantly higher in VTE patients compared with controls with a resulting pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38; p < 0.00001). Similar findings were obtained when the genotypes A1O/BO/A2B (OR 1.73, 95% CI, 1.47, 2.05; p < 0.00001) and A1B/A1A1/BB (OR 1.87, 95% CI, 1.84, 2.44; p < 0.00001) were analyzed. The maximum VTE risk was observed in non-O-factor V Leiden patients (OR 7.60, 95% CI, 3.21, 17.99), while for G20210A prothrombin mutation it was not possible to perform a pooled analysis due to a paucity of published studies. Finally, the association between non-O blood group and VTE was weaker when provoked VTE cases were considered (OR 1.33, 95% CI, 1.18, 1.50), while it was substantially unchanged when unprovoked VTE cases were analyzed (OR 1.88, 95% CI, 1.42, 2.50). In conclusion, considering its prevalence, non-O blood group is a candidate to be one of the most important genetic risk factors for venous thrombosis. |
| Author | Dentali, Francesco Sironi, Anna Paola Turato, Sara Franchini, Massimo Bonfanti, Carlo Crestani, Silvia Ageno, Walter Frattini, Francesco |
| Author_xml | – sequence: 1 givenname: Francesco surname: Dentali fullname: Dentali, Francesco organization: Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy – sequence: 2 givenname: Anna Paola surname: Sironi fullname: Sironi, Anna Paola – sequence: 3 givenname: Walter surname: Ageno fullname: Ageno, Walter – sequence: 4 givenname: Sara surname: Turato fullname: Turato, Sara – sequence: 5 givenname: Carlo surname: Bonfanti fullname: Bonfanti, Carlo – sequence: 6 givenname: Francesco surname: Frattini fullname: Frattini, Francesco – sequence: 7 givenname: Silvia surname: Crestani fullname: Crestani, Silvia – sequence: 8 givenname: Massimo surname: Franchini fullname: Franchini, Massimo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22740183$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAQhi1UREthZUQeWQz-Suqwoap8SBVdCmtkO2cIxHGxnaH_ngiKxHB6b3j0nO49RZM-9IDQBaPXjBbFTSKUCk6YYMWiUEdoxmilSEVLOfm3T9FpSh-UMqkoP0FTzheSMiVmyD-Hnmyw6UJocN7vALcJ53fANng_nkoZv0EPubU4tukTO21ziNiN87pd3eIIaehywi4GjzX2kDXRve72afQE96Pq2gxR5yHCGTp2uktwfsg5erlfbZePZL15eFrerYkVVZWJKJxrSsOMMsY1VFSCG2kEF5oy0IxbRhtTMaEY8EZZ0KUsS6ecYlY6WVI-R1e_3l0MX8P4RO3bZKHrdA9hSDWjXPBKUqlG9PKADsZDU-9i63Xc138V8W9og2o_ |
| CitedBy_id | crossref_primary_10_1182_blood_2024025923 crossref_primary_10_1016_j_envres_2022_113463 crossref_primary_10_1016_j_thromres_2019_11_002 crossref_primary_10_3390_ijms21124259 crossref_primary_10_3389_fimmu_2019_02891 crossref_primary_10_1016_j_thromres_2020_01_017 crossref_primary_10_1097_MD_0000000000037429 crossref_primary_10_2147_IJGM_S451087 crossref_primary_10_1016_j_jons_2018_09_001 crossref_primary_10_1007_s11239_013_0995_8 crossref_primary_10_1016_j_thromres_2017_05_018 crossref_primary_10_1007_s00701_021_05079_5 crossref_primary_10_1016_j_thromres_2016_05_015 crossref_primary_10_1177_10760296251364267 crossref_primary_10_1016_j_thromres_2014_05_016 crossref_primary_10_3390_jcm11020285 crossref_primary_10_1160_th14_05_0457 crossref_primary_10_1016_j_transci_2024_103925 crossref_primary_10_1038_srep23250 crossref_primary_10_2491_jjsth_36_505 crossref_primary_10_1038_s41598_024_64476_9 crossref_primary_10_1002_hsr2_70250 crossref_primary_10_1097_MD_0000000000023091 crossref_primary_10_1038_nrcardio_2013_211 crossref_primary_10_2174_03666220531142340 crossref_primary_10_1016_j_jhep_2015_07_026 crossref_primary_10_1111_jth_12057 crossref_primary_10_1111_jth_14874 crossref_primary_10_1177_2047487319876044 crossref_primary_10_1016_j_thromres_2019_10_025 crossref_primary_10_3389_fonc_2022_906427 crossref_primary_10_1007_s11239_013_1045_2 crossref_primary_10_1186_s43019_025_00284_3 crossref_primary_10_1111_vox_12786 crossref_primary_10_1155_2017_9237481 crossref_primary_10_1055_s_0040_1713753 crossref_primary_10_1097_MPH_0000000000000333 crossref_primary_10_1371_journal_pone_0294368 crossref_primary_10_1016_j_tracli_2022_10_003 crossref_primary_10_1007_s11239_015_1176_8 crossref_primary_10_1016_j_arth_2017_02_063 crossref_primary_10_1097_PCC_0000000000000107 crossref_primary_10_1177_1076029618770289 crossref_primary_10_1007_s11239_017_1576_z crossref_primary_10_1111_vox_13072 crossref_primary_10_1160_TH16_08_0634 crossref_primary_10_1136_bmjopen_2019_036040 crossref_primary_10_1016_j_thromres_2017_12_025 crossref_primary_10_1016_j_ejim_2013_10_002 crossref_primary_10_1016_j_avsg_2024_12_067 crossref_primary_10_1007_s00345_018_2351_2 crossref_primary_10_1161_CIRCGENETICS_114_000621 crossref_primary_10_1111_jth_13409 crossref_primary_10_1038_srep42925 crossref_primary_10_1016_j_nmni_2020_100763 crossref_primary_10_1111_joim_13256 crossref_primary_10_1016_j_thromres_2019_10_009 crossref_primary_10_1160_TH15_02_0141 crossref_primary_10_1371_journal_pone_0249252 crossref_primary_10_3390_medicina57121323 crossref_primary_10_1186_s13054_018_2022_0 crossref_primary_10_3390_diagnostics10100826 crossref_primary_10_1007_s11239_013_1027_4 crossref_primary_10_1007_s00068_021_01776_z crossref_primary_10_1007_s11239_012_0836_1 crossref_primary_10_3390_jcm11113064 crossref_primary_10_1002_pbc_29668 crossref_primary_10_1016_j_jvs_2017_03_415 crossref_primary_10_1186_s43168_020_00051_w crossref_primary_10_3390_jcm10163692 crossref_primary_10_1097_MCA_0000000000000676 crossref_primary_10_1038_s41598_021_95443_3 crossref_primary_10_1111_jog_14452 crossref_primary_10_1017_S0022149X18001116 crossref_primary_10_3390_clinpract12030045 crossref_primary_10_1007_s11239_023_02934_3 crossref_primary_10_1186_s12933_025_02669_w crossref_primary_10_3233_CH_211290 crossref_primary_10_1111_jth_12808 crossref_primary_10_1111_liv_15159 crossref_primary_10_1160_TH13_02_0112 crossref_primary_10_1155_2022_9088393 crossref_primary_10_1007_s11239_012_0783_x crossref_primary_10_1182_blood_2025028652 crossref_primary_10_1016_j_jtha_2023_07_009 crossref_primary_10_3389_fmed_2021_759648 crossref_primary_10_1002_emp2_13115 crossref_primary_10_3389_fcvm_2023_1224462 crossref_primary_10_1515_cclm_2013_0168 crossref_primary_10_1182_bloodadvances_2021006283 crossref_primary_10_1016_j_thromres_2014_03_054 crossref_primary_10_1111_vox_13427 crossref_primary_10_1590_1806_9282_20230386 crossref_primary_10_1038_s41467_020_19623_x crossref_primary_10_1080_17474086_2019_1583555 crossref_primary_10_17225_jhp00132 crossref_primary_10_1002_rth2_12671 crossref_primary_10_1080_17474086_2024_2306821 crossref_primary_10_1002_cam4_513 crossref_primary_10_1016_j_revmed_2016_10_118 crossref_primary_10_1111_jth_12379 crossref_primary_10_1186_s12944_025_02444_6 crossref_primary_10_1007_s11239_020_02090_y crossref_primary_10_1111_bjh_15060 crossref_primary_10_1016_j_jvssci_2021_08_002 crossref_primary_10_1259_bjr_20170560 crossref_primary_10_1080_10641963_2016_1267190 crossref_primary_10_1007_s00701_018_3489_9 crossref_primary_10_1002_rmv_2247 crossref_primary_10_1161_CIRCULATIONAHA_115_017563 crossref_primary_10_1177_1076029616683803 crossref_primary_10_1160_TH13_09_0780 crossref_primary_10_1007_s11239_012_0855_y crossref_primary_10_1016_j_mjafi_2018_01_008 crossref_primary_10_1161_STROKEAHA_120_030425 crossref_primary_10_1007_s10815_018_1185_6 crossref_primary_10_1186_s12916_024_03423_x crossref_primary_10_1007_s11033_014_3026_8 crossref_primary_10_1177_1129729820954721 crossref_primary_10_1177_17085381251360121 crossref_primary_10_1016_j_ehj_2017_03_002 crossref_primary_10_1111_jth_12464 crossref_primary_10_1177_00099228231157956 crossref_primary_10_1186_s12916_014_0250_y crossref_primary_10_1177_1076029620922913 crossref_primary_10_1371_journal_pone_0204331 crossref_primary_10_1016_j_ijcard_2019_01_090 crossref_primary_10_1016_j_healun_2017_05_016 crossref_primary_10_1016_j_amjcard_2015_05_043 crossref_primary_10_1097_MPH_0000000000001996 crossref_primary_10_1097_MBC_0000000000000101 crossref_primary_10_1073_pnas_1705762114 crossref_primary_10_1007_s00280_021_04252_y crossref_primary_10_1097_MCA_0000000000000564 crossref_primary_10_1016_j_cca_2015_02_016 crossref_primary_10_1038_s41467_025_62789_5 crossref_primary_10_1177_0961203317721352 crossref_primary_10_1177_1076029616672585 crossref_primary_10_1186_s12958_020_00685_x crossref_primary_10_1016_j_micpath_2022_105658 crossref_primary_10_2147_CMAR_S301458 crossref_primary_10_1160_th14_03_0199 crossref_primary_10_1007_s11239_017_1543_8 crossref_primary_10_1002_pbc_29581 crossref_primary_10_1111_trf_18342 crossref_primary_10_1371_journal_pone_0210732 crossref_primary_10_1111_jth_12234 crossref_primary_10_2217_pgs_2022_0164 crossref_primary_10_1007_s11239_019_02012_7 crossref_primary_10_1016_j_urology_2013_08_046 crossref_primary_10_1160_th15_06_0459 crossref_primary_10_1160_TH13_06_0488 crossref_primary_10_1016_j_ejmhg_2017_10_004 crossref_primary_10_1016_j_thromres_2015_05_002 crossref_primary_10_1038_ncomms14357 |
| ContentType | Journal Article |
| Copyright | Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. |
| Copyright_xml | – notice: Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1055/s-0032-1315758 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1098-9064 |
| ExternalDocumentID | 22740183 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- .GJ 0R~ 123 1UC 4.4 53G 5RE 5~~ AAIWL AAKAS AAQQT ABJNI ABOCM ABZLV ACGFO ACGFS ACNUY ADZCM AENEX AEVEF AGCGI AHRAW AHRSK AIVKU AJGCD AKJTW ALMA_UNASSIGNED_HOLDINGS BPGNG C45 CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD EXEOM F5P H13 IY8 J5H N9A NPM O9- OVD P2P Q3R QTC RIG ROL RTC TEORI TWZ UDS YFH ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c399t-35ffd6b1b8bbfd03932b4b323a01ea12c10db91381e2d8cea6466f8f81c4f4602 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 192 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000306086000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-9064 |
| IngestDate | Sun Nov 09 13:09:26 EST 2025 Sat Jun 28 01:33:46 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c399t-35ffd6b1b8bbfd03932b4b323a01ea12c10db91381e2d8cea6466f8f81c4f4602 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| PMID | 22740183 |
| PQID | 1023294048 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1023294048 pubmed_primary_22740183 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-07-01 |
| PublicationDateYYYYMMDD | 2012-07-01 |
| PublicationDate_xml | – month: 07 year: 2012 text: 2012-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Seminars in thrombosis and hemostasis |
| PublicationTitleAlternate | Semin Thromb Hemost |
| PublicationYear | 2012 |
| SSID | ssj0014802 |
| Score | 2.4467354 |
| SecondaryResourceType | review_article |
| Snippet | It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 535 |
| SubjectTerms | ABO Blood-Group System - genetics Genetic Predisposition to Disease Humans Prospective Studies Venous Thromboembolism - blood Venous Thromboembolism - genetics |
| Title | Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22740183 https://www.proquest.com/docview/1023294048 |
| Volume | 38 |
| WOSCitedRecordID | wos000306086000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--H-uLEbyGbdK0m3oRkRUPunpQ2duSJyzsS9v19ztps3oSBC-9tQ2TL5kvmZlvCLk0SIFTbSzNnNVUoEujOleWGnSH2iFBShrJ_IdOryf7_eI5XriVMa1ysSfWG7WdmnBH3g4SA7wQCLjr2TsNXaNCdDW20FgmqylSmYDqTv8niiBkzDkscFGj712INmZZu6QIZ05ZypCvyN_pZe1m7rb-O8BtshkJJtw0iNghS26yS9YfYwh9j4x70wl9gjphHcIFLAxLQBYI-JdxEO6vADEVShshpJ1D05AHkNvC20v3CvB4Ph9VJYS6FFAwdpWiKiqbwNTXnxp9azXvk9e77svtPY09F6hB-1U0zby3uWZaau1tKNzlWuiUpyphTjFuWGJ1wdDPO26lcSoXee6ll8wIL_KEH5CVCQ72iECipRHOJSoLZzyces8KXXCZ2LyQXHRa5GJhyAFiOgQq1MRN5-Xgx5QtctjMxmDWiG8MOA89BGV6_Ie3T8gG8puYXXtKVj2uaHdG1sxnNSw_zmuw4LP3_PgFEz3JFQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non-O+blood+type+is+the+commonest+genetic+risk+factor+for+VTE%3A+results+from+a+meta-analysis+of+the+literature&rft.jtitle=Seminars+in+thrombosis+and+hemostasis&rft.au=Dentali%2C+Francesco&rft.au=Sironi%2C+Anna+Paola&rft.au=Ageno%2C+Walter&rft.au=Turato%2C+Sara&rft.date=2012-07-01&rft.issn=1098-9064&rft.eissn=1098-9064&rft.volume=38&rft.issue=5&rft.spage=535&rft_id=info:doi/10.1055%2Fs-0032-1315758&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-9064&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-9064&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-9064&client=summon |